JP2014521600A - マイクロｒｎａ−３１組成物および自己免疫疾患に使用する方法 - Google Patents

マイクロｒｎａ−３１組成物および自己免疫疾患に使用する方法 Download PDF

Info

Publication number
JP2014521600A
JP2014521600A JP2014518912A JP2014518912A JP2014521600A JP 2014521600 A JP2014521600 A JP 2014521600A JP 2014518912 A JP2014518912 A JP 2014518912A JP 2014518912 A JP2014518912 A JP 2014518912A JP 2014521600 A JP2014521600 A JP 2014521600A
Authority
JP
Japan
Prior art keywords
expression
rhoa
subject
microrna
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014518912A
Other languages
English (en)
Japanese (ja)
Inventor
イーホン・ヤオ
シェン・ナン
ファン・ウェイ
タン・ユエンジア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Renji Hospital
Original Assignee
Shanghai Renji Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Renji Hospital filed Critical Shanghai Renji Hospital
Publication of JP2014521600A publication Critical patent/JP2014521600A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2014518912A 2011-06-27 2012-06-26 マイクロｒｎａ−３１組成物および自己免疫疾患に使用する方法 Pending JP2014521600A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161501482P 2011-06-27 2011-06-27
US61/501,482 2011-06-27
PCT/US2012/044197 WO2013003346A2 (fr) 2011-06-27 2012-06-26 Compositions de microarn-31 et leurs procédés d'utilisation dans des maladies auto-immunes

Publications (1)

Publication Number Publication Date
JP2014521600A true JP2014521600A (ja) 2014-08-28

Family

ID=47424764

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014518912A Pending JP2014521600A (ja) 2011-06-27 2012-06-26 マイクロｒｎａ−３１組成物および自己免疫疾患に使用する方法

Country Status (8)

Country Link
EP (1) EP2723349A4 (fr)
JP (1) JP2014521600A (fr)
KR (1) KR20140066671A (fr)
AU (1) AU2012275552A1 (fr)
BR (1) BR112013033794A2 (fr)
CA (1) CA2841158A1 (fr)
RU (1) RU2014102217A (fr)
WO (1) WO2013003346A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112843233A (zh) * 2019-11-26 2021-05-28 中国科学院上海营养与健康研究所 预防皮肤衰老与早衰的内源性小rna分子标靶及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1432724A4 (fr) * 2002-02-20 2006-02-01 Sirna Therapeutics Inc Inhibition a mediation par interference d'arn de genes de map kinase
CN101376910B (zh) * 2007-08-27 2012-01-11 中国科学院上海生命科学研究院 微小rna基因在系统性红斑狼疮疾病诊断和治疗中的作用
CA2745919A1 (fr) * 2008-12-05 2010-06-10 Whitehead Institute For Biomedical Research Compositions et procedes concernant le mir-31

Also Published As

Publication number Publication date
WO2013003346A2 (fr) 2013-01-03
KR20140066671A (ko) 2014-06-02
CA2841158A1 (fr) 2013-01-03
WO2013003346A3 (fr) 2013-02-28
AU2012275552A1 (en) 2014-02-06
EP2723349A4 (fr) 2015-01-14
RU2014102217A (ru) 2015-08-10
BR112013033794A2 (pt) 2019-09-24
EP2723349A2 (fr) 2014-04-30

Similar Documents

Publication Publication Date Title
ES2727549T3 (es) Tratamiento de las enfermedades relacionadas con la apolipoproteína a1 por inhibición del transcrito antisentido natural a la apolipoproteína a1
US10604755B2 (en) Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene
ES2727582T3 (es) Sistema para la utilización de energía de condensado
ES2760912T3 (es) Tratamiento de enfermedades relacionadas con la Sirtuina 1 (SIRT1) por inhibición del transcrito antisentido natural de la Sirtuina 1
US9534219B2 (en) Methods of treating vascular inflammatory disorders
EP2111449B1 (fr) Agents nucléotidiques de silençage de h19 destinés au traitement de l'arthrite rhumatoïde
US9789132B2 (en) Methods targeting miR-128 for regulating cholesterol/lipid metabolism
US9322015B2 (en) Methods of using microRNA-26a to promote angiogenesis
WO2020081585A1 (fr) Arn long non codant inca1 et ribonucléoprotéine nucléaire hétérogène homo sapiens h1 (hnrnph1) utilisés en tant que cibles thérapeutiques pour l'immunothérapie
JP2014521600A (ja) マイクロｒｎａ−３１組成物および自己免疫疾患に使用する方法
US10378015B2 (en) Targeting hepatitis B virus (HBV) host factors
WO2015138960A2 (fr) Ré-ingénierie moléculaire de l'équilibre excitation-inhibition dans des circuits mémoire
US20230287427A1 (en) Inhibition of lncExACT1 to Treat Heart Disease
US20210380988A1 (en) Reducing Prominin2-Mediated Resistance to Ferroptotic Cell Death
US20220282257A1 (en) Method of modulating adiposity
WO2024112653A1 (fr) Acides nucléiques inhibiteurs et leurs procédés d'utilisation
WO2020171889A1 (fr) Blocage de l'accumulation des lipides ou de l'inflammation dans la maladie oculaire thyroïdienne

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20141215